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296Objective: Vasoactive medications improve hemodynamics after cardiac surgery but are associated with high
metabolic and arrhythmic burdens. The vasoactive-inotropic score was developed to quantify vasoactive and
inotropic support after cardiac surgery in pediatric patients but may be useful in adults as well. Accordingly,
we examined the time course of this score in a substudy of the Biventricular Pacing After Cardiac Surgery trial.
We hypothesized that the score would be lower in patients randomized to biventricular pacing.
Methods: Fifty patients selected for increased risk of left ventricular dysfunction after cardiac surgery and ran-
domized to temporary biventricular pacing or standard of care (no pacing) after cardiopulmonary bypass were
studied in a clinical trial between April 2007 and June 2011. Vasoactive agents were assessed after cardiopul-
monary bypass, after sternal closure, and 0 to 7 hours after admission to the intensive care unit.
Results: Over the initial 3 collection points after cardiopulmonary bypass (mean duration, 131 minutes), the
mean vasoactive-inotropic score decreased in the biventricular pacing group from 12.0  1.5 to 10.5  2.0
and increased in the standard of care group from 12.5 1.9 to 15.5 2.9. By using a linear mixed-effects model,
the slopes of the time courses were significantly different (P ¼ .02) and remained so for the first hour in the in-
tensive care unit. However, the difference was no longer significant beyond this point (P ¼ .26).
Conclusions: The vasoactive-inotropic score decreases in patients undergoing temporary biventricular pacing in
the early postoperative period. Future studies are required to assess the impact of this effect on arrhythmogen-
esis, morbidity, mortality, and hospital costs. (J Thorac Cardiovasc Surg 2013;146:296-301)The inotropic score was introduced by Wernovsky and col-
leagues1 as a quantitativemeasure of cardiovascular support
received by neonates after the arterial switch operation. The
score has since been used to assess illness severity in infants
and neonates undergoing cardiothoracic surgery.2-8 Gaies
and colleagues9 recently introduced the vasoactive-
inotropic score (VIS), which expanded on the inotrope
score to include other vasoactive agents commonly used
in intensive care units (ICUs). The authors showed that
the VIS was superior to the older inotrope score as a surro-
gate outcome measure for infants undergoing cardiac sur-
gery. However, the VIS has not been evaluated in the
adult population as a measure of cardiovascular support or
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The Journal of Thoracic and Cardiovascular SurgVasoactive and inotropic medications currently are useful
for the treatment of hypotension and low output states after
cardiac surgery. These agents may improve cardiac output
but at the significant cost of increases in myocardial oxygen
consumption (MVO2), arrhythmias, systemic hypoperfu-
sion, and risk of myocardial ischemia and necrosis.10-13
Biventricular pacing (BiVP) is an established therapy for
select patients with chronic congestive heart failure, im-
proving clinical end points (symptoms, exercise capacity,
quality of life, survival) and echocardiographic end points
(systolic function, left ventricular size, mitral regurgita-
tion).14-17 Temporary BiVP also has been shown to
improve intraoperative cardiac output in patients
undergoing cardiac surgery.18-22 One unexplored benefit
of BiVP is its potential to decrease the use of inotropes
and vasoactive medications after cardiac surgery. BiVP
does not increase MVO2 and thus may provide a safer
alternative to inotropic medications.11
The Biventricular Pacing After Cardiac Surgery (Bi-
PACS) trial is a randomized clinical trial studying the effect
of optimized temporary BiVP in selected patients undergo-
ing cardiac surgery.18-21 Patients undergo BiVP
optimization at 3 time points in the postoperative period
and are randomized to continuous optimized BiVP or
standard of care (SOC) (no pacing). The central
hypothesis is that the cardiac index will increase an
average of 15% in the optimized BiVP group.ery c August 2013
TABLE 1. Baseline characteristics
Characteristic
Randomized
to BiVP
(n ¼ 24)
Randomized
to SOC
(n ¼ 26)
P
value
Mean age, y (range) 69.0 (49-85) 66.8 (48-87) .46
Female,% 17% 23%
Median BMI, kg/m2 (range) 25.3 (19-46) 26.4 (16-41) .77
Mean weight (kg) 78.5 (48-123) 76.4 (50-104) .66
Mean CPB time (min) 133.0 (57-325) 132.5 (68-239) .83
Mean crossclamp time (min) 90.9 (0-235) 77.8 (0-210) .35
Type of surgery*
CABG (32) 13 19 .17
Aortic valve replacement (27) 15 12 .26
Mitral valve repair or
replacement (22)
11 11 .61
BiVP, Biventricular pacing; SOC, standard of care (no pacing); BMI, body mass in-
dex;CPB, cardiopulmonary bypass;CABG, coronary artery bypass grafting. *Several
patients underwent combined surgery.
Abbreviations and Acronyms
BiPACS ¼ Biventricular Pacing After Cardiac
Surgery
BiVP ¼ biventricular pacing
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
MVO2 ¼ myocardial oxygen consumption
SOC ¼ standard of care
VIS ¼ vasoactive-inotropic score
VISmax ¼ maximum vasoactive-inotropic score
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DIn this BiPACS substudy, we hypothesized that tempo-
rary BiVP would lower the perioperative requirements for
vasoactive medication support, as measured by the VIS.
Although temporary BiVP has been shown to improve
postoperative hemodynamics, there have been no studies in-
vestigating whether it reduces the need to administer perio-
perative inotropic agents.MATERIALS AND METHODS
Study Design
The BiPACS protocol was approved by the Institutional Review Board for
Human Subject Research at Columbia University Medical Center and con-
ducted under an Investigational Device Exemption from the Food and Drug
Administration.Attending surgeonpermissionwasobtainedbefore approach-
ing patients for enrollment. Written consent was obtained from all patients.
This unblinded observational studywas conducted using a subgroup anal-
ysis for eligible patients enrolled in the BiPACS trial between October 1,
2007, and June 30, 2011. Patient flow for the BiPACS trial and this substudy
cover recruitment during this time period.A total of 5101 patients underwent
cardiac surgery at Columbia University Medical Center and were screened
for theBiPACS trial. Of these patients, 764were eligible for theBiPACSpro-
tocol; 105 patients were enrolled. The studywas initiated in 57 patients, who
were allocated to testing in phase I and subsequently randomized to BiVP
(experimental group) or SOC (control group) as per the BiPACS protocol.
Patients were randomized after phase I testing confirmed that BiVP was
feasible. To avoid imbalances using simple randomization, patients were
randomized to the 2 arms using randomly permuted blocks of 4, 6, and
8. A treatment allocation ratio of 1 was used, expecting each group to be
of equal size. Phase 1 testing was done in all patients before randomization
and has been described.21 Group assignment was determined by forms in
sealed envelopes opened at the randomization point. All required forms
were prepared before the enrollment of the first patient. Seven patients
were eliminated from this substudy because they were removed from the
BiPACS trial before the start of phase III. In the end, 24 patients random-
ized to the BiVP group and 26 patients randomized to the SOC group were
available and included in this substudy. The baseline clinical characteristics
of these 50 patients are shown in Table 1.
Biventricular Pacing After Cardiac Surgery
Optimization Protocol
The BIPACS trial is delineated by optimizations at 3 distinct time
points21 to determine the optimal pacing site, atrioventricular delay, and in-
terventricular delay (Figure 1). Phase I optimization is performed after the
patient is separated from CPB and deemed hemodynamically stable by the
clinical team. Phase II optimization is performed during sternal closure at
the end of the surgery. Finally, phase III optimization is performed 8 to 24The Journal of Thoracic and Cahours after phase II optimization. Patients are randomized to the optimized
BiVP group or the SOC group at the end of phase I optimization. Phase I
optimization is performed using cardiac output by aortic flow probe, phase
II is performed using mean arterial pressure, and phase III optimization is
performed using a combination of mean arterial pressure and cardiac out-
put by thermodilution. During periods of BiVP optimization (8 minutes
during phase I and 16 minutes during phase II), the rates of administration
of fluids, blood products, anesthetics, and vasoactive medications are held
constant, except for windows for adjustment between optimization of indi-
vidual parameters.
Anesthesia Protocol
General endotracheal anesthesia is used for all patients, and dosing is at
the discretion of the attending anesthesiologist. Fentanyl and midazolam
are used as adjunct agents to attenuate autonomic responses. Inotropes, va-
sopressors, and vasodilators are administered at the discretion of the attend-
ing anesthesiologist on the basis of hemodynamics and real-time
transesophageal echocardiography. In general, norepinephrine infusion is
the first-line vasoconstrictor, and vasopressin infusion is added if additional
vasoconstriction is desirable. The primary inotropic agent is milrinone. The
majority of patients undergoing coronary artery bypass grafting with the
use of bilateral internal thoracic arteries receive a low-dose (5 mg/min) ni-
troglycerin infusion at the conclusion of CPB. This infusion is maintained
for at least 24 hours postoperatively.
Vasoactive-Inotropic Score
We used a modification of the VIS described by Gaies and colleagues.9
The score at each time point was based on the concurrent doses and types of
inotropic and vasopressor medication being administered. We expanded
this formula to include the vasopressor phenylephrine and chose its coeffi-
cient in the same manner as originally described by Wernovsky and col-
leagues.1 The VIS is calculated as follows:
VIS ¼ dopamine doseðmg=Kg=minÞþ dobutamine doseðmg=Kg=minÞ
þ 100 3 epinephrine doseðmg=Kg=minÞ
þ 10 3 milrinone doseðmg=Kg=minÞ
þ 10;000 3 vasopressin doseðU=Kg=minÞ
þ 100 3 norepinephrine dose ðmg=Kg=minÞ
þ 10 3 phenylephrine doseðmg=Kg=minÞ:
Specific vasoactive agents used are presented in Table 2. We normalized
dosages for patient weight as described previously.2,7,8rdiovascular Surgery c Volume 146, Number 2 297
FIGURE 1. Time course of BiPACS protocol. During phase I, after weaning from CPB, the protocol maximizing cardiac output was determined. This
protocol was designated P1. Patients were randomized after phase I into the BiVP or SOC arm. Patients in the BiVP arm were paced under P1 until phase
II. During phase II, after sternal closure, the protocol maximizing mean arterial pressure was determined and designated P2. Pacing was then resumed using
P2 in the BiVP arm until phase III optimization, at which point the study period was concluded. VIS was calculated before randomization (VIS1), before
phase II (VIS2), on relocation from the operating room to the ICU (VIS3), and hourly when the patient was in the ICU (VIS4-VIS10). VIS, Vasoactive-
inotropic score; CPB, cardiopulmonary bypass; SC, sternal closure; CTICU, cardiothoracic intensive care unit.
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mization. VIS2 is calculated immediately preceding phase II optimiza-
tion. VIS3 is calculated on entry into the ICU. VIS4 to VIS10 are then
calculated hourly until the end of the study period (immediately preced-
ing phase III optimization) (Figure 1). The average time between the on-
set of phase I and the onset of phase II was 66  30 minutes, and the
average time between the onset of phase II and entry into the ICU was
65  35 minutes.TABLE 2. Vasoactive agents used by phaseMaximum Vasoactive-Inotropic Score
The VIS is calculated for each hour the patient spent in the ICU. The
maximum VIS (VISmax) is defined as the highest VIS before phase III.Time Vasoactive agent
Randomized
to BiVP
(n ¼ 24)
Randomized
to SOC
(n ¼ 26)
Entering phase I (OR) Dopamine 0 (0%) 1 (4%)
Dobutamine 1 (4%) 2 (8%)
Epinephrine 2 (8%) 3 (12%)
Milrinone 14 (58%) 17 (65%)
Norepinephrine 21 (88%) 22 (85%)
Vasopressin 18 (75%) 21 (81%)
Phenylephrine 2 (8%) 1 (4%)
Entering phase II (OR) Dopamine 0 (0%) 1 (4%)
Dobutamine 1 (4%) 2 (8%)
Epinephrine 2 (8%) 3 (12%)
Milrinone 14 (58%) 17 (65%)
Norepinephrine 21 (88%) 23 (88%)
Vasopressin 17 (71%) 22 (85%)
Phenylephrine 2 (8%) 1 (4%)
Before phase III (ICU) Dopamine 0 (0%) 2 (8%)
Dobutamine 3 (13%) 2 (8%)
Epinephrine 3 (13%) 5 (19%)
Milrinone 14 (58%) 17 (65%)
Norepinephrine 22 (92%) 22 (85%)
Vasopressin 19 (79%) 23 (88%)
Phenylephrine 1 (4%) 3 (12%)
BiVP, Biventricular pacing; SOC, standard of care (no pacing); OR, operating room;
ICU, intensive care unit.Other Variables
Urine output produced for each patient after CPB was determined by
measuring the volume of urine in the catheter bag on admission to ICU.
The patient’s serum glucose levels were measured hourly in the ICU.
Statistical Analysis
The VIS was compared between the BiVP group and the SOC group un-
der linear mixed-effects models where VIS was the outcome and pacing
group (BiVP vs SOC) and time (since the start of phase I) were the 2
main predictors. Pacing group by time interaction was also included in
the initial model but excluded from the final model if not significant. The
analysis also included the subject random effects to account for within
subject correlation on the VIS. In addition, the VISmax was calculated for
each patient after arrival into the ICU and before the start of phase III.
The VISmax was compared between the BiVP group and the SOC group us-
ing an independent 2-sample t test. All the analyses were conducted in SAS
version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS
Figure 2 illustrates the variation of the mean VIS for pa-
tients in the temporary BiVP and SOC groups from the
end of CPB to admission into the ICU. Both groups enter
phase I with a similar VIS, but the scores subsequently
diverge, increasing in the SOC group and decreasing in
the BiVP group. The difference in mean VIS between298 The Journal of Thoracic and Cardiovascular Surgthe SOC and BiVP groups is statistically significant
(P ¼ .02) from the beginning of phase I to the entry
into the ICU (mean duration, 131 minutes). This repre-
sents a significant interaction between pacing group and
time. There were no significant baseline differences be-
tween the 2 groups, as shown in Table 1. In particular, pa-
tient weight was the same, which is important, given the
per-weight dosing of medications.ery c August 2013
FIGURE 2. Diverging time course from randomization to ICU admission
in the SOC (n ¼ 26) and BiVP (n ¼ 24) groups. The VIS increased from
12.5  1.9 at randomization to 15.5  2.9 at ICU entry in the SOC group
but decreased from 12.0 1.5 to 10.5 2.0 in the BiVP group. The slopes
of these VIS–time relations are significantly different by linear mixed-
effects analysis (P ¼ .02). The time averaged 66  30 minutes between
phase I and II and 65 35 minutes between phase II and ICU entry. Pacing
was optimized at time points VIS1 and VIS2. VIS, Vasoactive-inotropic
score; ICU, intensive care unit; BiVP, biventricular pacing; SoC, standard
of care.
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2 groups from the point of randomization to 7 hours after
entry into the ICU. Pacing optimization for patients in the
BiVP group was not repeated after sternal closure until
phase III, which was later than the data in Figure 3. The ob-
servation period in the ICU was based on the BiPACS
protocol, which ended if the Swan-Ganz catheter (EdwardsFIGURE 3. VIS from randomization to 7 hours after ICU entry. Hourly average
slopes of the VIS–time relations are significantly different to the first hour in the
time points VIS1 and VIS2. Data collection was limited to 7 hours after ICU entry
removal occurred at this time. VIS, Vasoactive-inotropic score; ICU, intensive ca
ing; SoC, standard of care.
The Journal of Thoracic and CaLifeSciences, Irvine, Calif) was removed or after 24 hours
in the ICU, whichever came first. To standardize the data,
the VIS was computed only through the first 7 hours, which
all patients had in common. The data were analyzed under
a piecewise linear mixed-effects model with the focal time
period being 1 hour after entrance into the ICU. The differ-
ence in the change of VIS between the BiVP group and
SOC, measured each hour, remains significant up to the first
hour in the ICU, which extends the therapeutic effect of
BiVP as measured by the VIS to a total of 3 hours after
randomization (Figure 3, P ¼ .0015).
Group differences in the VIS after 1 hour in the ICU are
no longer statistically significant (P ¼ .26). This P value
represents an insignificant difference in pacing group effect,
although the time effect was significant (coefficient¼ 0.28,
P ¼ .02).
When the mean VISmax is compared between the 2
groups, there is a trend toward a lower VISmax in the
BiVP group, but the difference is not significant (BiVP
mean, 17.6  2.5; SOC mean, 22.4  4.3; P ¼ .33).
Urine output from the conclusion of CPB to ICU admis-
sion was significantly higher in patients randomized to
BiVP than in patients randomized to SOC (7.0  1.7 mL/
h/kg vs 2.6 0.5 mL/h/kg, P¼ .012). The concurrent max-
imal glucose levels were similar in both groups (168  8
mg/dL vs 181  13 mg/dL, respectively, P ¼ .42).DISCUSSION
Previous data from the BiPACS trial have demonstrated
the hemodynamic superiority of temporary BiVP versuss of the VIS are shown for the SOC (n¼ 26) and BiVP (n¼ 24) groups. The
ICU by linear mixed-effects analysis (P¼ .0015). Pacing was optimized at
because earliest Swan-Ganz catheter (Edwards LifeSciences, Irvine, Calif)
re unit; CTICU, cardiothoracic intensive care unit; BiVP, biventricular pac-
rdiovascular Surgery c Volume 146, Number 2 299
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DSOC, as judged by increases in cardiac output or mean
arterial pressure.21,23 However, changes in inotrope and
vasoactive agent use associated with temporary BiVP
were not examined.
Thepresent results demonstrate decreasingVIS in the tem-
porary BiVP group versus the SOCgroup over time, suggest-
ing that superior hemodynamics resulted in the decreased
administration of inotropes and vasoactive agents. We have
not defined a mechanism for the implied feedback of hemo-
dynamics on the rate of infusion of vasoactive drugs, and use
of these agents is not regulated by protocol at Columbia Uni-
versityMedicalCenter. Becauseweaning of vasoactive drugs
is generally based on the time course of arterial pressure,
urine output, and cardiac output, we speculate that differ-
ences in VIS between our patient groups reflect the patient
care team’s perception of changes in these parameters.
Although several previous studies have demonstrated he-
modynamic benefits related to temporary BiVP, demonstra-
tion of benefits in outcome has been elusive. However,
Gaies and colleagues9 reported that VISmax in the ICU
can predict morbidity and mortality; thus, the present re-
sults suggest that such benefits might be demonstrable in
a larger study. Inotropes and vasopressors in the periopera-
tive period can support cardiac output, regulate myocardial
contractility, improve hemodynamics, and reduce left and
right ventricular filling pressures.10 However, inotropes
are proarrhythmic and increase MVO2. The latter can in-
duce myocardial ischemia and adversely affect reperfusion
injury after CPB.10-13 Under well-controlled conditions,
BiVP can increase ventricular function without increasing
MVO2,11 an appealing aspect of this therapy.
The present results demonstrate that adults who receive
optimized temporary BiVP require lower levels of vasoac-
tive and inotropic support during the early postoperative pe-
riod (Figures 2 and 3). This could reflect increased cardiac
output in patients receiving temporary BiVP versus SOC.
Because inotropes are linked to arrhythmogenesis, reduced
use during the early postoperative period could decrease the
patient’s risk of a complicating arrhythmia. The reduced use
of inotropes is further beneficial in reducing MVO2 and
thus decreasing the chance of reperfusion injury after CPB.
Our results suggest that the benefit of temporary BiVP
pacing begins immediately and remains significant as
long as the pacing protocol is optimized hourly. We find
a statistically significant reduction in vasoactive and inotro-
pic support in the BiVP group for 2 hours after the last op-
timization of pacing. This suggests that deterioration of the
effects of temporary BiVP may be due to the lack of contin-
ued pacing optimization, and further indicates that effects of
temporary BiVP would be maximized by continuous opti-
mization during the postoperative period.
In addition, a significant increase in urine output was ob-
served for the BiVP group versus the SOC group from the
beginning of phase I to entry into the ICU. Although this300 The Journal of Thoracic and Cardiovascular Surgstudy was not designed for a multifactorial assessment of
factors affecting urine output, this result, which mirrored
our VIS analysis, further supports the postoperative cardio-
vascular benefit of optimized temporary BiVP.
The VIS was validated in pediatric patients undergoing
cardiac surgery as a marker of inotropic support and an es-
tablished predictor of outcome.9,24 However, until now,
there have been no studies using this updated vasoactive
inotrope score in the adult population. The VIS in adults
is expected to differ from the VIS in infants because the
response of cardiac muscle and vasculature to inotropic
and vasopressor mediations differs between pediatric and
adult patients.25 The VIS clearly merits further evaluation
as an adjunct to management of adult patients after CPB.
The present results also support the value of temporary
BiVP as an inotrope replacement. Further studies are
needed of both the VIS in adults and the hemodynamics
of temporary BiVP after CPB.
It is important to note that the VIS focuses on the amount,
not the specific types, of vasoactive and inotropic support.
Specific agents are used at the individual clinician’s discre-
tion to improve outcome and severity of illness. This non-
standardized protocol cannot be controlled for in
a retrospective study such as ours, so prospective random-
ized trials are necessary to account for selection bias and op-
timize the strategy for implementing specific medications.
Study Limitations
There are several additional limitations to our study. This
study is part of the larger BiPACS trial. An independent jus-
tification of sample size for this substudy would be based on
anticipated differences in the VIS between the 2 groups and
on the variance of the VIS. This would define an ideal sam-
ple size larger than presented in the current study. Termina-
tion of the parent trial precludes additional data collection.
However, statistical significance was achieved by fitting lin-
ear effects models over time and comparing the slope. An-
esthesiologists were not blinded to the 2 arms of the study;
however, they were also not aware that the VIS would be
evaluated. In addition, this is a single-center study, and
thus our findings may not be generalizable to other patient
populations.
CONCLUSIONS
Our results show that optimized temporary BiVP after
CPB lowers the requirement for inotropic support in the
early postoperative period, therefore decreasing the expo-
sure to inotrope-associated risks. The VIS can be useful in
post-CPB management and pacing intervention as a tool
to quantify vasoactive and inotropic support, as well as a po-
tential measure of cardiovascular function. The VIS has the
potential to be a component of a multivariable severity of
illness scoring system, which would be particularly useful
to practitioners trying to decide between various diagnosticery c August 2013
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surgery with BiVP. Additional studies are required to show
a correlation between VIS and outcomes, such as arrhyth-
mias, morbidity, or mortality.References
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